Journal
MOLECULAR & CELLULAR PROTEOMICS
Volume 8, Issue 9, Pages 2023-2033Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/mcp.R800016-MCP200
Keywords
-
Categories
Funding
- CNRS Departement de la politique industrielle
- Ministere de L'Education Nationale
- de L'Enseignement Superieur et de la Recherche
- Institut National du Cancer
- Agence National de la recherche
- Canadian Institutes of Health Research
Ask authors/readers for more resources
A decade after its inception, MALDI imaging mass spectrometry has become a unique technique in the proteomics arsenal for biomarker hunting in a variety of diseases. At this stage of development, it is important to ask whether we can consider this technique to be sufficiently developed for routine use in a clinical setting or an indispensable technology used in translational research. In this report, we consider the contributions of MALDI imaging mass spectrometry and profiling technologies to clinical studies. In addition, we outline new directions that are required to align these technologies with the objectives of clinical proteomics, including: 1) diagnosis based on profile signatures that complement histopathology, 2) early detection of disease, 3) selection of therapeutic combinations based on the individual patient's entire disease-specific protein network, 4) real time assessment of therapeutic efficacy and toxicity, 5) rational redirection of therapy based on changes in the diseased protein network that are associated with drug resistance, and 6) combinatorial therapy in which the signaling pathway itself is viewed as the target rather than any single node in the pathway. Molecular & Cellular Proteomics 8: 2023-2033, 2009.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available